CoChat

Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

Open access
Watanabe, Hiroki, Ozasa, Neiko, Morimoto, Takeshi, Shiomi, Hiroki, Bingyuan, Bao, Suwa, Satoru, Nakagawa, Yoshihisa, Izumi, Chisato, Kadota, Kazushige, Ikeguchi, Shigeru, Hibi, Kiyoshi, Furukawa, Yutaka, Kaji, Shuichiro, Suzuki, Takahiko, Akao, Masaharu, Inada, Tsukasa, Hayashi, Yasuhiko, Nanasato, Mamoru, Okutsu, Masaaki, Kametani, Ryosuke, Sone, Takahito, Sugimura, Yoichi, Kawai, Kazuya, Abe, Mitsunori, Kaneko, Hironori, Nakamura, Sunao, Kimura, Takeshi, on behalf of the CAPITAL-RCT investigators · 2018 · PLOS ONE
Cited by 131

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Despite its recommendation by the current guidelines, the role of long-term oral beta-blocker therapy has never been evaluated by randomized trials in uncomplicated ST-segment elevation myocardial infarction (STEMI) patients without heart failure, left ventricular dysfunction or ventricular arrhythmia who underwent primary percutaneous coronary intervention (PCI). METHODS AND RESULTS: In a multi-center, open-label, randomized controlled trial, STEMI patients with successful primary PCI within 24 hours from the onset and with left ventricular ejection fraction (LVEF) ≥40% were randomly assigned in a 1-to-1 fashion either to the carvedilol group or to the no beta-blocker group within 7 days after primary PCI. The primary endpoint is a composite of all-cause death, myocardial infarction, hospitalization for heart failure, and hospitalization for acute coronary syndrome. Between August 2010 and May 2014, 801 patients were randomly assigned to the carvedilol group (N = 399) or the no beta-blocker group (N = 402) at 67 centers in Japan. The carvedilol dose was up-titrated from 3.4±2.1 mg at baseline to 6.3±4.3 mg at 1-year. During median follow-up of 3.9 years with 96.4% follow-up, the cumulative 3-year incidences of both the primary endpoint and any coronary revascularization were not significantly different between the carvedilol and no beta-blocker groups (6.8% and 7.9%, P = 0.20, and 20.3% and 17.7%, P = 0.65, respectively). There also was no significant difference in LVEF at 1-year between the 2 groups (60.9±8.4% and 59.6±8.8%, P = 0.06). CONCLUSION: Long-term carvedilol therapy added on the contemporary evidence-based medications did not seem beneficial in selected STEMI patients treated with primary PCI. TRIAL REGISTRATION: CAPITAL-RCT (Carvedilol Post-Intervention Long-Term Administration in Large-scale Randomized Controlled Trial) ClinicalTrials.gov.number, NCT 01155635.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0199347

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 131

Metadata

Authors
Watanabe, H., Ozasa, N., Morimoto, T., Shiomi, H., Bingyuan, B., Suwa, S., Nakagawa, Y., Izumi, C., Kadota, K., Ikeguchi, S., Hibi, K., Furukawa, Y., Kaji, S., Suzuki, T., Akao, M., Inada, T., Hayashi, Y., Nanasato, M., Okutsu, M., Kametani, R., Sone, T., Sugimura, Y., Kawai, K., Abe, M., Kaneko, H., Nakamura, S., Kimura, T., & on behalf of the CAPITAL-RCT investigators
Venue
PLOS ONE
Published
2018-08-28
Volume
13
Issue
8
Pages
e0199347
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2889501145
Cited by
131
References
4
FWCI
3.44
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. https://app.cochat.ai/papers/10.1371/journal.pone.0199347
The paper
Watanabe, H., Ozasa, N., Morimoto, T., Shiomi, H., Bingyuan, B., Suwa, S., Nakagawa, Y., Izumi, C., Kadota, K., Ikeguchi, S., Hibi, K., Furukawa, Y., Kaji, S., Suzuki, T., Akao, M., Inada, T., Hayashi, Y., Nanasato, M., Okutsu, M., . . . on behalf of the CAPITAL-RCT investigators. (2018). Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLOS ONE. https://doi.org/10.1371/journal.pone.0199347

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.